Qin-Fen Chen, Lifen Chen, Christos S Katsouras, Chenyang Liu, Jingjing Shi, Dongjie Liang, Guangze Xiang, Han Zhu, Hetong Liao, Weihong Lin, Xi Zhou, Xiao-Dong Zhou
{"title":"1990-2021年204个国家和地区心力衰竭的全球负担及其根本原因。","authors":"Qin-Fen Chen, Lifen Chen, Christos S Katsouras, Chenyang Liu, Jingjing Shi, Dongjie Liang, Guangze Xiang, Han Zhu, Hetong Liao, Weihong Lin, Xi Zhou, Xiao-Dong Zhou","doi":"10.1093/ehjqcco/qcae110","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) presents a significant global health challenge due to its rising prevalence and impact on disability.</p><p><strong>Aims: </strong>This study aims to comprehensively analyze the global burden of HF and its underlying causes.</p><p><strong>Methods: </strong>Using data from the Global Burden of Disease Study 2021, we analyzed the prevalence and Years Lived with Disability (YLD) of HF, examining its implications across diverse demographics and geographic regions.</p><p><strong>Results: </strong>In 2021, approximately 55.5 million (95% UI 49.0-63.8) people worldwide were affected by HF, a significant increase from 25.4 million (95% UI 22.3-29.2) in 1990. The age-standardized prevalence rate per 100 000 people was 676.7 (95% UI 598.7-776.8) overall, with males experiencing a higher rate at 760.8 (95% UI 673.2-874.7) compared to females at 604.0 (95% UI 535.0-692.3). The age-standardized prevalence YLD rates increased by 5.5% (95% CI 2.7-8.5) and 5.9% (95% CI 2.9-9.0) during this period. Ischemic heart disease emerged as the primary cause of HF, with an age-standardized prevalence rate of 228.3 (95% UI 118.2-279.6), followed by hypertensive heart disease at 148.3 (95% UI 117.3-186.3), and cardiomyopathy/myocarditis at 62.0 (95% UI 51.2-73.2). Noteworthy, countries in the high Socio-Demographic Index (SDI) quintile exhibited higher HF prevalence rates but maintained stable trends. In contrast, countries in lower SDI quintiles, while initially experiencing lower prevalence rates, showed increased age-standardized HF prevalence and YLD rates over the same period.</p><p><strong>Conclusions: </strong>HF emerges as a significant and growing public health challenge globally, influenced by distinct socioeconomic gradients.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Global burden of heart failure and its underlying causes in 204 countries and territories, 1990-2021.\",\"authors\":\"Qin-Fen Chen, Lifen Chen, Christos S Katsouras, Chenyang Liu, Jingjing Shi, Dongjie Liang, Guangze Xiang, Han Zhu, Hetong Liao, Weihong Lin, Xi Zhou, Xiao-Dong Zhou\",\"doi\":\"10.1093/ehjqcco/qcae110\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Heart failure (HF) presents a significant global health challenge due to its rising prevalence and impact on disability.</p><p><strong>Aims: </strong>This study aims to comprehensively analyze the global burden of HF and its underlying causes.</p><p><strong>Methods: </strong>Using data from the Global Burden of Disease Study 2021, we analyzed the prevalence and Years Lived with Disability (YLD) of HF, examining its implications across diverse demographics and geographic regions.</p><p><strong>Results: </strong>In 2021, approximately 55.5 million (95% UI 49.0-63.8) people worldwide were affected by HF, a significant increase from 25.4 million (95% UI 22.3-29.2) in 1990. The age-standardized prevalence rate per 100 000 people was 676.7 (95% UI 598.7-776.8) overall, with males experiencing a higher rate at 760.8 (95% UI 673.2-874.7) compared to females at 604.0 (95% UI 535.0-692.3). The age-standardized prevalence YLD rates increased by 5.5% (95% CI 2.7-8.5) and 5.9% (95% CI 2.9-9.0) during this period. Ischemic heart disease emerged as the primary cause of HF, with an age-standardized prevalence rate of 228.3 (95% UI 118.2-279.6), followed by hypertensive heart disease at 148.3 (95% UI 117.3-186.3), and cardiomyopathy/myocarditis at 62.0 (95% UI 51.2-73.2). Noteworthy, countries in the high Socio-Demographic Index (SDI) quintile exhibited higher HF prevalence rates but maintained stable trends. In contrast, countries in lower SDI quintiles, while initially experiencing lower prevalence rates, showed increased age-standardized HF prevalence and YLD rates over the same period.</p><p><strong>Conclusions: </strong>HF emerges as a significant and growing public health challenge globally, influenced by distinct socioeconomic gradients.</p>\",\"PeriodicalId\":11869,\"journal\":{\"name\":\"European Heart Journal - Quality of Care and Clinical Outcomes\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-01-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Heart Journal - Quality of Care and Clinical Outcomes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ehjqcco/qcae110\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal - Quality of Care and Clinical Outcomes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjqcco/qcae110","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Global burden of heart failure and its underlying causes in 204 countries and territories, 1990-2021.
Background: Heart failure (HF) presents a significant global health challenge due to its rising prevalence and impact on disability.
Aims: This study aims to comprehensively analyze the global burden of HF and its underlying causes.
Methods: Using data from the Global Burden of Disease Study 2021, we analyzed the prevalence and Years Lived with Disability (YLD) of HF, examining its implications across diverse demographics and geographic regions.
Results: In 2021, approximately 55.5 million (95% UI 49.0-63.8) people worldwide were affected by HF, a significant increase from 25.4 million (95% UI 22.3-29.2) in 1990. The age-standardized prevalence rate per 100 000 people was 676.7 (95% UI 598.7-776.8) overall, with males experiencing a higher rate at 760.8 (95% UI 673.2-874.7) compared to females at 604.0 (95% UI 535.0-692.3). The age-standardized prevalence YLD rates increased by 5.5% (95% CI 2.7-8.5) and 5.9% (95% CI 2.9-9.0) during this period. Ischemic heart disease emerged as the primary cause of HF, with an age-standardized prevalence rate of 228.3 (95% UI 118.2-279.6), followed by hypertensive heart disease at 148.3 (95% UI 117.3-186.3), and cardiomyopathy/myocarditis at 62.0 (95% UI 51.2-73.2). Noteworthy, countries in the high Socio-Demographic Index (SDI) quintile exhibited higher HF prevalence rates but maintained stable trends. In contrast, countries in lower SDI quintiles, while initially experiencing lower prevalence rates, showed increased age-standardized HF prevalence and YLD rates over the same period.
Conclusions: HF emerges as a significant and growing public health challenge globally, influenced by distinct socioeconomic gradients.
期刊介绍:
European Heart Journal - Quality of Care & Clinical Outcomes is an English language, peer-reviewed journal dedicated to publishing cardiovascular outcomes research. It serves as an official journal of the European Society of Cardiology and maintains a close alliance with the European Heart Health Institute. The journal disseminates original research and topical reviews contributed by health scientists globally, with a focus on the quality of care and its impact on cardiovascular outcomes at the hospital, national, and international levels. It provides a platform for presenting the most outstanding cardiovascular outcomes research to influence cardiovascular public health policy on a global scale. Additionally, the journal aims to motivate young investigators and foster the growth of the outcomes research community.